Harrow Inc. (HROW)

A volatile stock. A recent drug launch has been good, though a little slower than expected. There's a lot of competition, but he expects growth. They so well buying companies and striking relationships with doctors. 

HROW had a iss on earnings of $0.22 vs $0.26 expected and revenue was a bit shy at $71.6 vs $73.7 expected. There was a bit of a disruption in one of their businesses leading to the miss on the quarter but the branded business is seeing momentum and good volumes showing robust demand looking forward. The company also recently closed the MELT acquisiton which should be a tailwind in the next year. The current quarter itself was on the weaker side but markets like the outlook here. 
Unlock Premium - Try 5i Free  

HROW had a iss on earnings of $0.22 vs $0.26 expected and revenue was a bit shy at $71.6 vs $73.7 expected. There was a bit of a disruption in one of their businesses leading to the miss on the quarter but the branded business is seeing momentum and good volumes showing robust demand looking forward. The company also recently closed the MELT acquisiton which should be a tailwind in the next year. The current quarter itself was on the weaker side but markets like the outlook here. 
Unlock Premium - Try 5i Free  

HROW had a iss on earnings of $0.22 vs $0.26 expected and revenue was a bit shy at $71.6 vs $73.7 expected. There was a bit of a disruption in one of their businesses leading to the miss on the quarter but the branded business is seeing momentum and good volumes showing robust demand looking forward. The company also recently closed the MELT acquisiton which should be a tailwind in the next year. The current quarter itself was on the weaker side but markets like the outlook here. 
Unlock Premium - Try 5i Free  

It is in the eye care business and focuses on ophthalmology and biotech. One question is how easily can they get drugs to patients. Their first interesting drug is for dry eyes and the second is an anesthetic for surgeries, especially cataract surgery. This one is stable and consistent from patient to patient. Other anesthetics vary in their length of time they are effective from patient to patient. Has stable cash flows from its compounding business and accelerating growth from key products. Could get from under $300 million in revenue today to $1 billion in revenue in the next four years as well as tripling margins.         Buy 8  Hold 0  Sell 0